Test host directed therapies for COVID-19 via rapid, efficient, collaborative adaptive platform trials aimed at helping to prevent infection, slow or halt disease progression, and speed recovery.
Fully integrate major NHLBI networks under one organizational umbrella to ensure efficiencies; standardization; collaboration; and sharing of control groups (as appropriate), resources, and data.
NHLBI directed Program integrated with NIH ACTIV and conducted in collaboration with BARDA, Operation Warp Speed, and as appropriate, other Institutes of Health.
Eli Lilly and Company (NYSE: LLY) today announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies broadly available to patients.
Read More
I was at the point where I didn't think I was going to make it. I was really bad, suffering with the breathing and everything...
Read More
A team of Duke Health clinicians that include faculty from the Department of Medicine are working diligently in a collaborative effort to enroll patients in a randomized, controlled trial, testing a novel antibody treatment for COVID-19.
Read More